Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00427440 | A Phase II Study to Treat Advanced Malignant Glioma | PHASE2 | COMPLETED | 61 | — | — | Nov 1, 2006 | Apr 1, 2013 | Apr 27, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| AMG 102 at 10 mg/kg Dose Level | EXPERIMENTAL | Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed. |
| AMG 102 at 20 mg/kg Dose Level | EXPERIMENTAL | Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed. |
| Name | Type | Description |
|---|---|---|
| AMG 102 at 20 mg/kg | DRUG | AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks |
| AMG 102 at 10 mg/kg | DRUG | AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks |
Inclusion Criteria: * subjects with documented histologically confirmed primary grade 4 advanced malignant glioma * no more than 3 prior relapses or prior systemic treatments * recurrent disease documented by MRI after prior therapy * must have at least one site of bidimensionally measurable diseas...